Accurate transcription by RNA pol III requires TFIIIB, while BRF2 is a component of TFIIIB. The regulation of pol III is integral to the growth control functions of RB, P53 and c-Myc, and TFIIIB activity is strictly regulated by Maf1, chemopreventative agents, oncogenes and tumor suppressors. BRF2 has been shown to be highly overexpressed in a variety of cancers including gastric, kidney and melanoma cancers. Recently, Lockwood et al. reported that overexpression of BRF2 could drive the expression of RNA pol III transcripts, contributing to squamous cell carcinoma tumorigenesis, and BRF2 has been identified as a novel lineage-specific oncogene in lung squamous cell carcinoma. However, to our knowledge, the expression of BRF2 and its correlation with clinicopathologic factors and prognosis in surgically resected NSCLC have not been investigated. In this study, we employed immunohistochemical method to examine BRF2 protein expression in clinical NSCLC samples, and 
we analyzed the relationships of BRF2 expression with variable clinicopathologic features and patient prognosis. Moreover, we assessed the independent prognostic factors that affect long-term survival of NSCLC patients. The ability to proliferate uncontrollably is the dominant characteristic of many types of cancer cells. Evaluation of molecular prognostic factors is one important area of cancer research. BRF2 protein is encoded by a gene located on chromosome 8p12. Several studies have shown that BRF2 is overexpressed in several types of cancer and suggest the oncogenic role of BRF2. However, few studies have investigated the expression and significance of BRF2 in NSCLC, especially for the prognosis of NSCLC. In this study, our results showed that there was no Tubuloside-A significant correlation between BRF2 expression and the clinicopathological features of NSCLC. However, high MVD was significantly associated with T status in NSCLC, but not associated with age, gender, smoking, histology and differentiation. To a certain extent, T stage is a critical process of tumor development, and the difference in the correlation between MVD and clinicopathological features may reflect that the microvessel density is an important aspect of tumor development. However, we found no significant difference in BRF2 expression between lung adenocarcinoma and lung squamous cell carcinoma by immunohistochemical staining. Notably, our results showed that BRF2 protein overexpression was common in early NSCLC tissues and significantly associated with increased angiogenic activity measured as intratumoral MVD, suggesting that BRF2 plays crucial role in NSCLC tumorigenesis by the induction or/and promotion of tumor angiogenesis. Although multiple growth factors have been shown to regulate angiogenesis and vascular development, little is known about the complex regulation mechanism of gene expression and translation. Our results highlight the potential role of BRF2 in tumor angiogenesis. Our survival analysis demonstrated that high MVD and BRF2 protein overexpression significantly predicted Tenuifoliside-C decreased overall 5-year survival and higher recurrence rate. Further analysis using the Cox regression model confirmed that BRF2 expression and MVD were independent factors.